ArticleTransfusion2026
Using blood donor surveillance and clinical case data to shape our understanding of Babesia epidemiology in Manitoba, Canada.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBabesia is a parasite transmitted by the Ixodes tick and has the potential to be transfusion transmitted. Climate change and changing Ixodes tick distributions in Canada raised questions about the impact of Babesia on the blood supply. Following a risk-based decision making (RBDM) process, Canadian Blood Services initiated a multi-year Babesia nucleic acid test (NAT) surveillance program in 2024. The first year of the project focused on a region (Manitoba, Canada) previously determined by the RBDM analysis to be of highest risk for Babesia NAT-positive donations. The aim of this study is to provide an update on this multi-year surveillance project that will shape our understanding of Babesia epidemiology in multiple Canadian provinces. STUDY DESIGN AND
methodsFrom July 11, 2024 to November 9, 2024, samples were collected in Roche Whole Blood Collection tubes at all whole blood donation sites in Manitoba. Specimens underwent one-time individual testing on the cobas Babesia NAT on the Roche cobas 6800 platform (Roche Diagnostics GmbH, Mannheim, Germany). Clinical cases of babesiosis were reviewed for the period 2013-2025.
resultsOf the 13,608 (98%) whole blood donations tested by Babesia NAT, none were positive. Clinical case rates of babesiosis in Manitoba ranged from 0 to 0.13 per 100,000 population annually. DISCUSSION: Changing climate and Ixodes tick distributions have led to concerns that the epidemiology of Babesia infection in Canadian blood donors is increasing. Babesia NAT on specimens from an elevated-risk area for Babesia infection in Canada did not identify Babesia-positive blood donors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.